As prostate cancer specialists, we’re dedicated to helping you, the patient, by delaying symptoms and maximising life expectancy without metastases. As the most common form of cancer in Europe, prostate cancer affects hundreds of thousands of people – we’re here to provide pioneering support for you or your loved ones.
Our Understanding of Prostate Cancer
Prostate cancer is the most common cancer in men across Europe. Within the region it represents 25% of all new male cancer cases diagnosed, and in 2018 alone approximately 450,000 men were diagnosed with the disease., There is a clear need for more transformational medicines, so that one day the words “you have prostate cancer” will be less frightening for people to hear.
PC-3 human prostate cancer cells, stained with Coomassie blue
Our Goal in Prostate Cancer
At Janssen, we’ve been actively engaged in transforming the future of prostate cancer care for close to a decade. From our first approval in 2011, we have continued to build on the insights from our clinical research, leading us to now having five approved indications in prostate cancer.,
One of our key goals in this area is to extend the time living without metastases and maintain the quality of life for those people who have received a diagnosis of prostate cancer, in different stages, so that we can ensure the best outcomes for them.
At Janssen, we have a legacy of innovation in the treatment of prostate cancer, which is the most common cancer in men across Europe.
We’re fighting hard across the entire spectrum of prostate cancer to bring the right treatment to the right patient and at the right time. In advanced disease stages, we are uniquely committed to helping as many people as possible throughout the entire prostate cancer journey.
Within our clinical trial programme we are pioneering new methods to our medicine evaluation and approval. We are exploring innovative approaches, such as using novel intermediate endpoints, which could lead to the development of potentially life-saving therapies.
Each Patient is Different
It is important to recognise that prostate cancer is an evolving disease. Each person and their cancer are unique and, as such, we don’t take a one-size-fits-all approach to treatment. Our focus is on providing treatment options that delay progression, prolong life and support a better quality of life for our patients.
For patients diagnosed with an advanced form of the disease and for those at high-risk of disease progression, prostate cancer sadly, too often leads to death., This is why we are committed to providing innovative treatment solutions across all disease stages.
There is no universal approach to cancer treatment, which is why we are committed to understanding the differences in patients’ clinical and non-clinical characteristics and how this can impact the therapeutic benefit of our medicines. Recent advances in our understanding of human biology and diseases may potentially improve treatment outcomes for patients through precision medicines.
We are pioneering a cutting-edge approach to our scientific methodologies and technologies, which enables us to adapt our discovery and development initiatives to drive our next wave of innovation. With our portfolio in prostate cancer, we are always striving for pioneering approaches in the approval of our medicines, to ensure these can be made available to patients as quickly as possible.
We are pushing the boundaries of our understanding of prostate cancer and unlocking new ways to tackle it before it can take hold in the body. When it comes to treating cancer, it's long been known that catching the disease in its early stages is key for a more successful outcome. The premise behind the new strategy, known as cancer interception, is to figure out why some healthy cells turn cancerous, so medications can be developed to interrupt that process – and potentially thwart the disease before it invades the body.
Janssen has earned worldwide recognition for its innovation and leadership in this area, with an unwavering commitment that spans more than 30 years.
Improving quality of life
While increasing overall survival remains a key focus, patient quality of life is always at the forefront of our minds. For us, helping to give patients more valuable time with their loved ones, to enjoy more of life’s meaningful moments, is what makes our work truly worthwhile. We have already seen the development of trials that incorporate early intermediate endpoints, such as metastasis-free survival., Metastases are a major cause of symptoms, complications and deaths in prostate cancer, so delaying their onset could lead to both an increase in survival and a slowdown in progression.
We are also combining Big Data and Artificial Intelligence (AI) to help analyse prostate cancer patient data collected in electronic health records in several European, Middle Eastern and African countries. This allows us to more accurately understand and describe the epidemiology, diagnosis and management of prostate cancer, as well as help inform our future approaches to research and treatment combinations.
We are dedicated to collaborating with likeminded businesses and organisations across the globe who share our vision of making cancer a preventable and curable disease by providing transformational therapeutic and diagnostic products and resources.
Working with cross-industry partners, such as Astex Therapeutics, we are bringing to life our commitment to precision medicines. These partnerships include leveraging computational tools and AI to provide state-of-the-art, real-world evidence to enable superior decision-making in managing illness.
Patterns, correlations and new hypothesis identified through AI will be incorporated into clinical trials, making them more efficient, accurate and safe. The use of Big Data is particularly relevant for prostate cancer due to the multiple, interacting biological, epidemiological, clinical, environmental, psychosocial and lifestyle-related variables that exist in a long-term disease course.
Through the ORACULUM study, Janssen is exploring AI/NLP to help analyse prostate cancer patient data collected in electronic health records in several European, Middle Eastern and African countries. This allows us to more accurately understand and describe the epidemiology, diagnosis, management and outcomes of patients with prostate cancer along the entire disease pathway in real word practice, as well as to identify potential prognostic and predictive factors of response.
ORACULUM is highly complementary to other big data initiatives running in parallel on prostate cancer (PIONEER Consortium) that are supported by the European Union through the Innovative Medicines Initiative (IMI).
In addition to this, Janssen is also collaborating with nine other pharmaceutical companies from across the industry in the Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY) project, which seeks to solve the challenges of data sharing within pharmaceutical research, while also significantly advancing drug discovery through predictive models.